Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + durvalumab sequential therapy after adjuvant modified FOLFIRINOX in HRR-mutated resected pancreatic adenocarcinoma
ChiCTR2200055702Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Disease-free survival. Started Nov 2021; status: recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2200055702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055702.